<DOC>
	<DOC>NCT01059591</DOC>
	<brief_summary>This is the first study in Humans with GSK424887 to evaluate what effects, good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body (pharmacokinetics). Also the study aims to investigate the penetration of the drug in the human brain by using PET (Positron Emission Tomography) imaging technology</brief_summary>
	<brief_title>First Study in Humans With GSK424887</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Healthy males aged 1845 years, limited to 2540 years for PET section The subject has a positive: drug/alcohol, Hepatitis, HIV screen The subject has a history of psychiatric illness suicidal attempts or behaviour. Abuse of alcohol. Clinically significant laboratory, ECG abnormality; The subject has recently received an investigational. Use of prescription or nonprescription drugs, History or presence of allergy to the study drug or drugs of this class,. Donation of more than 500 mL blood within the 90 days before dosing. An unwillingness of male subjects to comply with contraceptive requirements Average daily caffeine intake exceeding Protocol requirements.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>First time in Human</keyword>
	<keyword>Safety</keyword>
	<keyword>Healthy subjects</keyword>
	<keyword>NK1 antagonist and SSRI</keyword>
</DOC>